SCHEMBL22732771

SCHEMBL22732771

Cc1nc(-c2ccc(CC3CC3)cc2)nc(N)c1C(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ RPS6KB1 P23443 2/20 0.33
▸ LMNA P02545 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ RXRA P19793 2/20 0.32
▸ NR4A2 P43354 2/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ GRM2 Q14416 1/20 0.32
▸ DPP4 P27487 1/20 0.32
▸ LIPE Q05469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22732767 0.81 RXRA (0.36) KDM4EKMT2ARAB9AMEN1NPC1
SCHEMBL22732850 0.77 RAB9A (0.45) KDM4EKMT2ARAB9AMEN1NPC1
SCHEMBL22732774 0.77 S1PR1 (0.36) KDM4EKMT2ARAB9AMEN1NPC1
SCHEMBL22712508 0.77 KDM4E (0.51) KDM4EKMT2ARAB9AMEN1NPC1
SCHEMBL22732508 0.73 RAB9A (0.54) KDM4EKMT2ARAB9AMEN1NPC1
SCHEMBL22732833 0.73 KDM4E (0.35) KDM4EKMT2ARAB9AMEN1NPC1
SCHEMBL26936228 0.72 — —
SCHEMBL22732859 0.72 RAB9A (0.39) KDM4EKMT2ARAB9AMEN1NPC1
SCHEMBL22732509 0.70 RAB9A (0.36) KDM4EKMT2ARAB9AMEN1NPC1
SCHEMBL26936148 0.69 S1PR1 (0.40) KMT2AMEN1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4289480-A2 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS F. Hoffmann-La Roche AG (CH) 2023-12-13 — — EP disclosed
US-20220135528-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS GENENTECH, INC. (US AND US TERRITORIES) 2022-05-05 — — US disclosed
US-11208387-B2 Macrocyclic broad spectrum antibiotics GENENTECH, INC. (US) 2021-12-28 — — US disclosed
US-20200377463-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS GENENTECH, INC. 2020-12-03 — — US disclosed
WO-2020243155-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS GENENTECH, INC. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377463-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, CLPP, PEPD KDM4E 1982/4885KMT2A 3444/4885RAB9A 2950/4885
US-20220135528-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, CLPP, PEPD KDM4E 1982/4885KMT2A 3444/4885RAB9A 2950/4885
US-11208387-B2 Macrocyclic broad spectrum antibiotics MRPL21, CLPP, PEPD KDM4E 1982/4885KMT2A 3444/4885RAB9A 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback